

PRESS RELEASE

André Choulika to Serve as both Chairman and CEO of Cellectis

Paris, June 27, 2011 – Cellectis (Alternext: ALCLS), the French genome engineering specialist, announces that its Board has adopted a transfer of Chairmanship to CEO André Choulika. André Choulika takes over from Christian Policard, who is to stay on as a Director.

"I would like to thank Christian Policard who applied all his extensive experience and expertise in the last years to support the growth of the company ", said André Choulika. "Today Cellectis is entering a new phase and, together with our Board of Directors, our management team and entire workforce, I will work to transform the company into an industrial group."

Christian Policard has added: « During my six years as Chairman, Cellectis has strengthened its leading position and I wish the company all the success it deserves. I'm delighted that André Choulika, who has all my trust, will serve as Chairman. It was my wish and I will continue to offer Cellectis my energy as a Director."

André Choulika was the founder of Cellectis and has served as Chief Executive Officer since the company's inception. Dr. Choulika is a pioneer in the analysis and use of meganucleases to modify complex genomes. He has made many of the critical observations in the field and is an author of the most significant patents on the use of meganucleases. Dr. Choulika received a Ph.D. in Molecular Virology from the University of Paris VI / Institut Pasteur. Dr. Choulika conducted post-doctoral studies at the Harvard Medical School within the department of Molecular Medicine of Boston's Children's Hospital.

About Cellectis

Cellectis improves life by applying its genome engineering expertise to a broad range of applications, including human therapeutics, bioresearch and agriculture. Cellectis is listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris. More information at www.cellectis.com.



Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

Press release I Cellectis I genome engineering

For further information, please contact:

Cellectis

Sylvie Delassus Senior VP Corporate Communication +33 (0)1 41 83 99 00 +33 (0)6 26 54 33 18 media@cellectis.com